Compass Pathways Plc ADR
Chiusa
12.49 -1.26
Panoramica
Variazione del prezzo dell'azione
24h
Minimo
12.33
Massimo
13.48
Entrata | 185M 91M |
|---|---|
EPS | -0.3 |
Dipendenti | 156 |
EBITDA | 139M 93M |
Raccomandazioni | Fortemente da comprare |
|---|---|
Previsioni per 12 mesi | +85.77% upside |
Utili prossimi | 30 lug 2026 |
|---|
Capitalizzazione di Mercato | 428M 1.7B |
|---|---|
Apertura precedente | 13.75 |
Chiusura precedente | 12.49 |
Compass Pathways Plc ADR Grafico
Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.
Chi Siamo Compass Pathways Plc ADR
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
